Shanghai RAAS Blood Products Co., Ltd.
002252
Pozycja w akcjach
#3641
Shanghai RAAS Blood Products Co., Ltd. engages in the research, development,... Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnostic reagents, and testing services. The company was founded by Kieu Hoang on October 29, 1988 and is headquartered in Shanghai, China.
Cena akcji
$0.70717976
Kapitalizacja rynkowa
$4.66B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-24.71%
Kraj
CN
Handel Shanghai RAAS Blood Products Co., Ltd. (002252)
Kategoria
Healthcare
Zyski dla Shanghai RAAS Blood Products Co., Ltd. (002252)
Zyski w Jun 2026 TTM: $217.03M
Według najnowszych raportów finansowych Shanghai RAAS Blood Products Co., Ltd., obecny zysk firmy wynosi $217.03M. W roku 2023 firma osiągnęła zysk w wysokości $311.37M, spadek w porównaniu do zysku z roku 2022, który wynosił $329.61M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Shanghai RAAS Blood Products Co., Ltd. od 2005 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $217.03M | -39.54% |
| 2024 | $358.96M | 15.28% |
| 2023 | $311.37M | -5.53% |
| 2022 | $329.61M | 36.12% |
| 2021 | $242.14M | 7.08% |
| 2020 | $226.13M | 114.78% |
| 2019 | $105.29M | -141.25% |
| 2018 | $-255.27M | -265.29% |
| 2017 | $154.43M | -45.28% |
| 2016 | $282.21M | 4.77% |
| 2015 | $269.37M | 177.16% |
| 2014 | $97.19M | 248.88% |
| 2013 | $27.86M | -34.34% |
| 2012 | $42.43M | 13.57% |
| 2011 | $37.36M | 11.62% |
| 2010 | $33.47M | 43.19% |
| 2009 | $23.37M | 28.12% |
| 2008 | $18.24M | 35.94% |
| 2007 | $13.42M | 74.83% |
| 2006 | $7.68M | 1.12% |
| 2005 | $7.59M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | 2,330.53% |
US
|
|
| $-3.09B | -1,522.40% |
US
|
|
| $-4.02B | -1,950.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 798.81% |
NL
|
